Results 21 to 30 of about 2,803,213 (206)
Pulmonary Circulation, 2020 Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson +8 more
doaj +1 more source
Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
Frontiers in Pharmacology, 2020 Allergic rhinitis/rhinosinusitis (AR) is the most common allergic disease. It affects patients’ quality of life and may influence the severity of lower airway disease such as asthma. Therefore, its treatment is of great importance.
Viera Janosova +5 more
doaj +1 more source
PDE5 inhibitor drugs for use in dementia
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment.
Atticus H. Hainsworth +4 more
doaj +1 more source
In silico identification of potential natural product inhibitors of human proteases key to SARS-CoV-2 infection [PDF]
Molecules 2020, 25(17), 3822, 2020 Presently, there are no approved drugs or vaccines to treat COVID-19 which has spread to over 200 countries and is responsible for over 3,65,000 deaths worldwide. Recent studies have shown that two human proteases, TMPRSS2 and cathepsin L, play a key role in host cell entry of SARS-CoV-2.
arxiv +1 more source
Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
Frontiers in Pharmacology, 2020 PDE4 inhibitors can suppress a variety of inflammatory cell functions that contribute to their anti-inflammatory actions in respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma.
J. Phillips
semanticscholar +1 more source
Nonsteroidal anti-inflammatory drugs as potential ecto-nucleotide phosphodiesterase inhibitors
Brazilian Journal of Pharmaceutical Sciences, 2020 Phosphodiesterases (PDE) are group of enzymes which catalyze the hydrolysis of cAMP and cGMP. Since these cyclic phosphate moieties worked as intracellular second messengers in numerous physiological processes, their inhibition can affect normal ...
Shumaila Tasneem +2 more
doaj +1 more source
International Cardiovascular Forum Journal, 2019 Phosphodiesterases (PDEs) comprise a superfamily with 11 subfamilies. Within these families, more than 40 isoforms are expressed. Phosphodiesterase-3 inhibitors (PDE3i) are used as inotrope/vasodilators for acute heart failure (HF), and PDE5i for ...
R. Plácido, M. Lainščak
semanticscholar +2 more sources
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review
Journal of Ophthalmic & Vision Research, 2021 Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non ...
Francisco Barroso +2 more
doaj +1 more source
Phosphonic acid-containing inhibitors of tyrosyl-DNA phosphodiesterase 1
Frontiers in Chemistry, 2022 Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs stalled type I topoisomerase (TOP1)-DNA complexes by hydrolyzing the phosphodiester bond between the TOP1 Y723 residue and the 3′-phosphate of its DNA substrate.
Xue Zhi Zhao +6 more
doaj +1 more source
Simulations Suggest Pharmacological Methods for Rescuing Long-Term Potentiation [PDF]
Journal of Theoretical Biology, 7 Nov 2014, pp. 243-250, 2014 Congenital cognitive dysfunctions are frequently due to deficits in molecular pathways that underlie synaptic plasticity. For example, Rubinstein-Taybi syndrome (RTS) is due to a mutation in cbp, encoding the histone acetyltransferase CREB-binding protein (CBP).
arxiv +1 more source